Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (688)	10/20/1999 3:44:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 1494

The company says that this year's stockholders meeting is scheduled for November 11. I spoke to reception and she said she'd ask VP Lisa Carr to return my call. Reception was able to tell me that results of the Memantine diabetic neuropathic pain Phase IIB trial are expected to be released by the end of this year. Results for the AIDS-related dementia and neuropathic pain Phase II trial are expected in the Spring. Enrollment in the Xerecept Peritumoral Brain Edema Phase II trial has closed. Reception didn't have any further details (Lisa should, though), except that they will be updating the website shortly. I'll post more if Lisa returns my call. Marc